Articles tagged with Eye Diseases
Scientists discovered characteristic amyloid plaques in human retinas and developed a noninvasive optical imaging technique to detect retinal plaques in live laboratory mice. The study suggests the possibility of early noninvasive diagnosis and monitoring of Alzheimer's disease through retinal imaging.
Women who follow a balanced diet rich in essential vitamins and minerals have a lower risk of developing nuclear cataracts. A study of 1,808 women found that healthy diets, which reflect adherence to US dietary guidelines, are more strongly related to the occurrence of nuclear cataracts than other modifiable risk factors.
A new study reveals increasing rates of age-related macular degeneration among Asians, comparable to Caucasians. An innovative laser surgery called 'bypass' has shown promise in improving vision outcomes for central retinal vein occlusion patients.
The Los Angeles Latino Eye Study found that US Latinos develop visual impairment, blindness, diabetic eye disease, and cataracts at higher rates than non-Hispanic whites. Researchers also identified specific risk factors for these conditions, including diabetes and age.
Researchers developed a novel noninvasive tool using fluorescent microspheres to detect early inflammation in the eyes. This breakthrough allows for early detection of diseases such as eye disease, potentially reversing damage before it occurs. The tool may also improve therapy evaluation and extend to other areas of the body.
Scientists have successfully applied optical coherence tomography (OCT) to analyze the layers of easel paintings, revealing evidence of forged signatures and alterations. This non-invasive technique overcomes previous limitations, offering a new way for art conservators to detect changes in artworks.
A new vision screening model, EyeSmart EyeCheck, will test for damage from eye diseases to detect undiagnosed visual impairment. The initiative aims to raise awareness and provide access to care for minority populations with limited access to health services.
Research confirms green tea catechins penetrate eye tissues, potentially protecting against glaucoma and other eye diseases. The study, published in Journal of Agricultural and Food Chemistry, found that these antioxidants absorbed by the eyes reduced oxidative stress for up to 20 hours.
The American Academy of Ophthalmology affirms the effectiveness of current retinopathy of prematurity (ROP) diagnosis and treatment practices. Early treatment has been shown to improve visual acuity outcomes for these vulnerable infants, supporting ongoing ROP research.
Certain children with Type 1 retinopathy of prematurity benefit from early treatment, showing improved vision at age 6. In contrast, those with Type 2 disease do not see a significant benefit from early treatment at this age.
Researchers have discovered three new genes associated with age-related macular degeneration, including two involved in the cholesterol pathway. The study increases understanding of DNA variations that predict individual risks of AMD and provides clues for developing effective therapies.
Researchers confirm that early treatment for selected infants with retinopathy of prematurity (ROP) improves their vision through 6 years of age. Doctors can identify high-risk infants by examining certain eye characteristics, such as blood vessel appearance and location.
Researchers found that people with floppy eyelid syndrome (FES) are at a higher risk of having obstructive sleep apnea (OSA), which can lead to oxygen deprivation and other health complications. The study also highlights the importance of recognizing FES as a potential indicator for OSA and treating patients accordingly.
Researchers tested mecamylamine, a topical drug, in a human clinical trial to treat diabetic macular edema. The study showed significant improvement in vision and biological effects in the retina in approximately 40% of participants.
Researchers discovered that crowding does not make peripheral vision random, but rather creates a 'blending' effect that makes the world appear more regular. This process can help improve the recognition of objects in crowded environments for people with central vision loss due to eye diseases.
Researchers found that postmenopausal women using HRT had a higher risk of cataract removal compared to those who never used the therapy. Additionally, smoking was linked to an increased risk of uveitis, a serious eye disease causing inflammation in the middle layer of the eye.
Researchers at Vanderbilt University Medical Center have found that the first sign of injury in glaucoma occurs in the brain, where neuronal communication with the optic nerve is compromised. This discovery offers new insights into the disease and potential treatment targets.
Scientists have confirmed that green tea catechins penetrate into tissues of the eye, raising the possibility of protection against glaucoma. Analysis of eye tissues showed significant absorption of individual catechins, with effects lasting up to 20 hours.
Scientists use optical coherence tomography to analyze artworks, uncovering forged signatures and altered inscriptions. This technique enables detection of subtle changes in easel paintings without damaging the artwork.
A recent study by Kaiser Permanente has compared the effectiveness of two AMD drugs, ranibizumab (Lucentis) and bevacizumab (Avastin), while a global report highlights retinal vein occlusion prevalence worldwide. Additionally, research reveals that central vision impairment significantly increases the risk of falls in older adults.
Researchers have developed a micro-implant that clears scar tissue and delivers progenitor cells to the eye, increasing cell survival by 9-fold. The implant's scaffolding uses electrospinning to produce biodegradable fibers with pockets containing enzymes that degrade local scar tissue.
A team of scientists has discovered a new link between a common form of inherited blindness and the AHI1 gene. They found that patients carrying a specific genetic alteration were more likely to have retinal blindness, and some forms may be treatable with gene therapy.
Scientists at the University of Kentucky have discovered that withaferin A can simultaneously target two key proteins, vimentin and GFAP, implicated in reactive gliosis. This finding could lead to new treatments for diseases such as multiple sclerosis, Alzheimer's disease, stroke, and traumatic brain injury.
A new eye test technique enables real-time measurement of brain cell death, refining diagnosis and tracking disease progress in Alzheimer's. The method uses fluorescent markers to directly observe retinal nerve cell death, which could lead to successful reversal of the disease with treatment.
A new study finds that fibrocytes, a type of immune cell, are present at higher frequencies in patients with Graves' disease, leading to scarring and inflammation in the orbit. This discovery may lead to new treatments targeting scarring or fibrosis.
A novel scleral lens has been shown to improve vision and quality of life for patients with severe cornea or ocular surface disease. The Boston Ocular Surface Prosthesis (BOS-P) was found to be clinically beneficial in a study conducted by Brandeis University researchers, who assessed 69 patients before and after fitting them with the ...
The study found that older women have almost twice as many immune-related proteins in their saliva than younger women. This discovery could lead to a simple, noninvasive test for diagnosing and treating age-related diseases in women.
Researchers at Yale University have identified a novel protective mechanism in photoreceptors that could help preserve vision in people with eye diseases. The study found that the activation of CREB1/ATF1 is part of this pathway, which was triggered by stress and can be activated by certain drugs.
A small group of patients with severe Graves' eye disease showed rapid improvement after treatment with rituximab, reducing inflammation and optic nerve damage. The study suggests that rituximab may offer sustained benefits as an alternative to high-dose steroids.
A national study found cataract surgery benefits AMD patients at all stages of the disease, improving vision in those with mild to advanced AMD. Steroid triamcinolone also showed promise in treating advanced DME, with improved vision in patients whose eyes had deteriorated despite standard treatment.
A recent study found that Iraq and Afghanistan veterans with TBI vision loss have significantly poorer quality of life than comparable civilians. Low-vision patients may also experience vivid visual hallucinations due to Charles Bonnet syndrome, which can be treated by ignoring the images or medication.
Dr. Michael W. Brennan leads a team of American physicians working with Iraqi physicians to provide improved care as the country recovers from war traumas. He has been instrumental in developing a national emergency medical system and mental health programs, transforming Iraq's medical education and patient care.
Researchers found that implantation of blue light-filtering IOLs at cataract surgery increased macular pigment levels, which may offer protection against age-related macular degeneration. The study suggests a strong scientific rationale for the benefits of blue light-filtering in reducing vision loss.
Studies suggest ophthalmologists should suspect visual variant Alzheimer's in patients with unusual or severe vision problems, particularly difficulty reading. Nearsighted individuals may be less susceptible to diabetic retinopathy due to reduced risks associated with longer axial length and deeper anterior eye chamber.
Glaucoma clinics face challenges in providing follow-up care to patients from diverse ethnic backgrounds, with long wait times and interpreter issues cited as major barriers. To address these issues, researchers suggest streamlining appointment procedures and resolving wait time and language obstacles.
Gene therapy has been shown to improve vision in children with Leber congenital amaurosis, a severe form of inherited retinal degeneration. The treatment resulted in significant improvements in both subjective and objective measurements of vision.
Researchers transform adult eye cells into artificial stem cells without introducing foreign genetic materials, offering a promising approach to treat degenerative diseases such as Parkinson's and heart disease. This technique could facilitate autologous cell transplantation, bypassing ethical concerns with embryonic stem cells.
Researchers have developed two experimental treatments that restored some vision to people with blinding eye diseases. A retinal prosthesis and fetal tissue transplant showed promise in human studies, improving visual acuity in several individuals with retinitis pigmentosa and age-related macular degeneration.
Researchers at University of Toronto have discovered a previously unidentified form of circulation within the human eye, which may provide important new insights into glaucoma. The discovery overthrows the idea that the eye is an immune privileged site due to the lack of lymphatics.
Research highlights improved vision in type 1 diabetes patients, a link between macular degeneration and coronary heart disease, and the impact of vision on well-being across the lifespan. Effective treatments and better management of blood glucose levels contribute to the positive trend.
The 20/20 Network will focus on developing new biomaterials, medical devices, and drug delivery systems for treating vision disorders. Researchers aim to improve treatment of vision loss with products like composite materials, ocular microgels, and contact lenses.
A small study of 101 patients found that a one-minute eye movement exam performed at the bedside worked better than an MRI to distinguish new strokes from other less serious disorders. The quick and low-cost test caught more strokes than the current gold standard, suggesting a way to improve care and avoid high costs.
A study found that children in Ethiopia who received azithromycin for trachoma had a 49% lower odds of death compared to those who didn't receive the antibiotic. The treatment may have reduced mortality from pneumonia, diarrhea, and malaria, major causes of death in children in trachoma-endemic areas.
Resolvyx Pharmaceuticals announced positive Phase 2 clinical study results for RX-10045, a resolvin administered as a topical eye drop for treating patients with chronic dry eye syndrome. The 28-day trial showed dose-dependent improvements in symptoms and signs of dry eye.
Scientists have designed a painless microneedle patch that can deliver vaccines and medications through the skin, offering a potential solution to painful injections. The patch uses tiny 'microneedles' to improve treatment of diseases such as diabetes and macular degeneration.
Researchers found that elevated arginase levels contribute to vascular eye damage in diabetic retinopathy by reducing nitric oxide production. Normalizing arginase levels could potentially halt disease progression by preventing inflammation and vascular constriction.
The study uncovered the unlikely genetic suspect, FOXC1, which critically contributes to Dandy-Walker malformation, a brain defect causing mental retardation and motor delays. The discovery provides new mechanisms and potentially improves treatment for the disorder, offering insights into embryonic brain development.
Researchers are exploring the use of anti-growth factor drugs to treat children's eye diseases, offering a new tool in the fight against vision loss. However, specialists warn that these drugs may pose serious side effects, particularly in young patients.
Researchers at the University of Oklahoma Health Sciences Center discovered a natural compound that restores balance in the eye to stop diabetic retinopathy, a disease affecting five million Americans. The treatment prevents leakage, blocks inflammation, and stops unwanted blood vessel growth.
Researchers at the Peninsula Medical School have received a £9,600 grant to continue studying the genetic causes of eye movement disorders. The team aims to identify genes that contribute to loss of eye movement in conditions like Duane syndrome.
A treatment that significantly slows the progression of eye injury in people with type 1 diabetes has been found. The treatment uses an antihypertensive medication commonly prescribed to treat high blood pressure, and was shown to slow diabetic eye damage in over 65% of participants.
Researchers at LSU Health Sciences Center identified the 15-LOX-1 enzyme, which produces neuroprotectin D1, a molecule that protects retinal cells key to vision. This discovery has potential applications in treating retinal degenerative diseases and neurodegenerative conditions like Parkinson's disease.
Researchers have discovered a new target for the diagnosis and treatment of age-related macular degeneration by blocking the activity of the CCR3 protein. This approach shows promise as a safer and more effective alternative to current treatments, which target vascular endothelial growth factor (VEGF).
Researchers have demonstrated the long-term safety and efficacy of human embryonic stem cell-derived retinal pigment epithelium in animal models of eye diseases. The therapy has shown functional rescue in both RCS rat and Elov14 mouse, with sustained visual function without tumor formation or untoward pathological reactions.
Researchers at the University of New South Wales used a simple contact lens to rehabilitate damaged eye surfaces by cultivating patients' own stem cells. The procedure significantly improved sight within weeks and has potential applications in other organs.
A study estimates that approximately 1.68 million US men over 50 years old suffer from dry eye disease, which increases with age and is associated with high blood pressure and certain medications. The prevalence of the condition rises significantly among older men, particularly those aged 75 and above.
Researchers identify protein-protein interaction as a key factor in vision loss among people with genetic diseases, including Bardet-Biedl Syndrome. The study provides a blueprint for unraveling variations in other genetic diseases.
The LUMINATE trials demonstrate the ability of LX211 to significantly improve chronic eye inflammation in patients with uveitis. The study results also show a safety profile for LX211, allowing it to be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease.
Age-related macular degeneration is projected to increase substantially by 2050, but new therapies may help mitigate its effects. Simulation modeling predicts that combining antioxidant vitamins for prevention and anti-VEGF and laser therapy can reduce the rate of visual impairment and blindness due to AMD from 0.73% to 0.48%.
A new study from the University of Gothenburg suggests that tracking a preterm infant's weekly weight gain can identify those at risk of developing eye disease ROP. The simple method could save money and allow for earlier detection, reducing the need for costly ophthalmological exams.